- Home
- ALVO vs JANX Comparison
ALVO vs JANX Comparison
Compare ALVO & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVO
- JANX
- Stock Information
- Founded
- ALVO 2013
- JANX 2017
- Country
- ALVO Luxembourg
- JANX United States
- Employees
- ALVO N/A
- JANX N/A
- Industry
- ALVO Biotechnology: Pharmaceutical Preparations
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- ALVO Health Care
- JANX Health Care
- Exchange
- ALVO Nasdaq
- JANX Nasdaq
- Market Cap
- ALVO 3.4B
- JANX 3.6B
- IPO Year
- ALVO N/A
- JANX 2021
- Fundamental
- Price
- ALVO $12.60
- JANX $55.17
- Analyst Decision
- ALVO Buy
- JANX Strong Buy
- Analyst Count
- ALVO 1
- JANX 11
- Target Price
- ALVO $18.00
- JANX $83.09
- AVG Volume (30 Days)
- ALVO 145.6K
- JANX 1.6M
- Earning Date
- ALVO 11-13-2024
- JANX 11-06-2024
- Dividend Yield
- ALVO N/A
- JANX N/A
- EPS Growth
- ALVO N/A
- JANX N/A
- EPS
- ALVO N/A
- JANX N/A
- Revenue
- ALVO $393,919,000.00
- JANX $13,049,000.00
- Revenue This Year
- ALVO $398.12
- JANX $40.27
- Revenue Next Year
- ALVO $44.73
- JANX N/A
- P/E Ratio
- ALVO N/A
- JANX N/A
- Revenue Growth
- ALVO 517.92
- JANX 54.12
- 52 Week Low
- ALVO $9.15
- JANX $7.79
- 52 Week High
- ALVO $18.00
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- ALVO 63.60
- JANX 47.52
- Support Level
- ALVO $11.70
- JANX $55.00
- Resistance Level
- ALVO $12.25
- JANX $59.72
- Average True Range (ATR)
- ALVO 0.28
- JANX 3.54
- MACD
- ALVO 0.13
- JANX -0.83
- Stochastic Oscillator
- ALVO 94.28
- JANX 6.56
About ALVO Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.